ArticleFrontiers in immunology2022

Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of

Lan Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.